Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to late-breaking research presented in a Hot Line session today at ESC...
European Society of Cardiology Sep 2 2024 Mineralocorticoid receptor antagonists reduced the risk of cardiovascular death or heart failure hospitalization in patients with HF and reduced ejection fraction and also in those with mildly reduced or preserved ejection fraction , according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
In 13,846 patients, MRAs reduced the risk of cardiovascular death or HF hospitalisation . There was a significant interaction by trials and treatment due to the greater efficacy in HFrEF compared with HFmrEF/HFpEF . The effects were consistent across all subgroups in the HFrEF and HFmrEF/HFpEF trials.
Heart Failure Receptor Cardiology Placebo Potassium Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cryoballoon ablation as effective as radiofrequency for atrial fibrillation in heart failure patientsCryoballoon (CB) ablation is as effective at reducing recurrences of atrial fibrillation (AF) and atrial tachycardia (AT) at 1-year, when compared to the current most widely used technique, radiofrequency (RF) ablation, in heart failure patients with a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line...
Read more »
Gene-related metabolic dysfunction may be driving heart arrhythmiaPatients with a common heart arrhythmia called atrial fibrillation could benefit from future treatments that target inefficiencies in heart cell metabolism, a new paper has found.
Read more »
Finerenone shows promise for heart failure with mildly reduced or preserved ejection fractionFinerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial led by investigators from Brigham and Women's Hospital, a founding member...
Read more »
Digital consultations improve medication optimization in heart failure patientsPatients with heart failure, a condition affecting more than 60 million worldwide, are four times more likely to receive the optimal combination of medications after 12 weeks of digital consultations.
Read more »
Digital consultations found to improve the rate at which heart failure patients receive optimal medicationPatients with heart failure, a condition affecting more than 60 million worldwide, are four times more likely to receive the optimal combination of medications after 12 weeks of digital consultations.
Read more »
Semaglutide shown to cut major adverse cardiovascular events in heart failure patientsSemaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.
Read more »